Pulse
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
NIFTY 5024,980.40+0.35%
SENSEX81,720.10+0.28%
NIFTY SHARIAH 254,850.15+0.42%
GOLD 24K (10g)₹75,420+0.38%
SILVER (1kg)₹88,400-0.12%
ACTIVE IPOS8 Open+38% GMP
TCS₹4,124.50+1.18%
INFY₹1,892.40+1.22%
USD/INR₹83.92-0.04%
GUJARAT KIDNEY N SUP SP L

GUJARAT KIDNEY N SUP SP L

NSE: GKSL
Medical Care FacilitiesHealthcareSMALL CAPMCap ₹1.48k Cr
₹187.37₹-2.27 (-1.20%)

Market Closed • NSE

Market cap₹1.48k Cr
Enterprise value₹1.51k Cr
P/E TTM73.77
P/B4.62
EPS TTM₹2.54
ROCE14.50%
D/E0.11
Dividend yield0.00%
Face value₹2.00
52W high₹209.80
52W low₹98.36
Price chart(1Y)
1Y Return:+48.78% (+₹61.43)
H: ₹209.8L: ₹123.21
1W+2.63%
1M+5.37%
3M+47.50%
6M+69.72%
Today at a glance

Day range

₹186.56₹193.39

52 week range

₹98.36₹209.80
Volume333.9K0.12x 20D avg
Free float50.00%-87.90% volume

GUJARAT KIDNEY N SUP SP L closed at INR187.37 (-1.2%) on volume 0.12x its 20-day average, trading 10.69% below its 52-week high.

Technical analysis
RSI (14)56.9Neutral (30–70)
MACDBEARISHBearish (Below signal)
ATR (14)₹9.54High
SMA 20₹183.31BULLISH
SMA 50₹167.61BULLISH
SMA 100₹148.70BULLISH
SMA 200₹130.87BULLISH
CPR bottom₹192.40
Pivot₹191.48
CPR top₹190.56
What changed recently?

2026-Q2

Q2 FY2026 Financial Results

PAT moved +10.4% QoQ

Shariah audit
Methodology: AAOIFI Shariah Standard No. 21
PASS4/4 criteria
Shariah Compliant
CriteriaNumeratorDenominatorValueThresholdStatus
Interest-bearing debt ratio₹29.0 Cr₹1.48k Cr1.96%≤ 33%PASS
Non-halal income ratio–₹82.0 Cr0.00%≤ 5%PASS
Illiquid assets ratio–₹298.0 Cr—≥ 20%PASS
Receivables ratio–₹298.0 Cr—≤ 49%PASS
Valuation & sector context
MetricCompanySector
P/E73.7737.00
Forward P/E——
P/B4.625.00
EV/EBITDA55.8018.00
PEG—1.00
Earnings yield1.402.70
Growth & profitability
RevenuePAT
FY24PAT margin 9.40%
FY25PAT margin 23.40%
FY26PAT margin 18.90%

Revenue and PAT bars use independent scales to make their year-on-year direction readable.

Revenue CAGR 3Y+26.80%
Revenue CAGR 5Y+75.00%
PAT CAGR 3Y+21.80%
PAT CAGR 5Y+53.40%
Operating margin20.24%
Net margin15.67%
Financial health & cash flow
Net debt₹29.0 CrHealthy
Interest coverage13.50xEBIT / interest
CFO / PAT0.14x3Y average
Net debt / EBITDA1.07xLeverage
Operating cash flow₹-400.0 Lakh
Capital expenditure–
Free cash flow₹-400.0 Lakh
Financial statements

Complete reported financial history · Values use the company's reporting currency

Hover over the chart for exact reported values. Percentage lines use the right-hand axis.

Fundamental scorecard
Overall65/100
Valuation35/100
Profitability65/100
Financial health95/100

A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.

Strengths, risks & investment thesis

Strengths

Low Debt Profile: Debt-to-Equity is comfortable at 0.11x

Risks

Stretched Valuation: Trading at a high P/E multiple of 73.8x

Bull case

Market Leadership: Established operational scale in Medical Care Facilities.

Bear case

Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.

Flip condition

Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.

Shareholding pattern
Quarterly ownership historyLatest valid period · December 2025

Ownership distribution

Dec 2025Latest holding

Category trends

Hover over a period for exact holdings

80%53%27%0%Dec 2025
5.45%Institutional holding
23.10%Public holding
1Periods available
0.00%Promoter pledged
18.3KShareholders
Delivery participation

Traded volume and delivery percentage across the latest 20 sessions

Average delivery (20D)35.80%-1.48% latest vs average
Highest delivery61.70%on 24 Sept
Average volume (20D)2.77MTrading-session average
Conviction trendWeakening-1.48% latest reading
Traded volumeDelivery %
Peer comparison

Compare valuation, latest quarterly performance and year-on-year growth

8 companies
Company nameMarket cap ₹ CrP/E ratioDividend yield %Quarterly sales ₹ CrProfit after tax ₹ CrSales growth %Profit growth %
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries LimitedSUNPHARMA
Open analysis
₹4.22L34.900.91%₹15,300.00₹2,901.00+10.46%+26.52%
Divi's Laboratories Limited
Divi's Laboratories LimitedDIVISLAB
Open analysis
₹2.43L82.970.33%₹3,080.00₹902.00+27.80%+65.50%
Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals LimitedTORNTPHARM
Open analysis
₹1.73L72.830.83%₹4,128.00₹389.00+41.90%-21.89%
Apollo Hospitals Enterprise Limited
Apollo Hospitals Enterprise LimitedAPOLLOHOSP
Open analysis
₹1.13L54.320.25%₹7,044.00₹610.00+20.58%+38.32%
Zydus Lifesciences Limited
Zydus Lifesciences LimitedZYDUSLIFE
Open analysis
₹1.12L25.030.09%₹8,017.00₹990.00+21.95%-34.91%
LENSKART SOLUTIONS LTD
LENSKART SOLUTIONS LTDLENSKART
Open analysis
₹1.12L174.730.00%₹2,714.00₹228.00+43.29%+273.77%
Laurus Labs Limited
Laurus Labs LimitedLAURUSLABS
Open analysis
₹1.11L101.830.12%₹2,026.31₹367.60+29.10%+125.49%
Cipla Limited
Cipla LimitedCIPLA
Open analysis
₹1.07L31.780.98%₹7,119.00₹786.00+2.33%-39.16%
About GUJARAT KIDNEY N SUP SP L
GUJARAT KIDNEY N SUP SP L

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]

IndiaHealthcare

Questions investors ask
Is GUJARAT KIDNEY N SUP SP L Shariah compliant?

GUJARAT KIDNEY N SUP SP L is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (1.96%) complies with AAOIFI threshold (≤ 33%).

What is GUJARAT KIDNEY N SUP SP L's current valuation relative to peers?

GUJARAT KIDNEY N SUP SP L trades at a P/E of 73.8x compared to the sector median of 37x, and a Price-to-Book of 4.6x.

Is the company financially healthy?

The company has a Debt-to-Equity ratio of 0.11x and a Net Debt to EBITDA ratio of 1.07x. Interest coverage is 13.5x.

What are the historical revenue and profit growth rates?

Over the past 5 years, revenue compounded at 75% while net profit growth averaged 53.4%.

Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.

Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.